Inclusion Criteria:

- Female patients, >/= 18 years of age

- Histologically or cyctologically confirmed epithelian ovarian cancer that is
platinum-resistant or refractory

- Low HER3 mRNA expression

- Eastern Cooperative Oncology Group (EOCD) performance status 0 to 2

- Left ventricular ejection fraction (LVEF) >/= 55%

- Negative serum pregnancy test in women of childbearing potential

- Women of childbearing potential must agree to use effective contraception as defined
by protocol during and for at least 6 months post study treatment

Exclusion Criteria:

- Non-epithelial tumors

- Ovarian tumors with low malignant potential (i.e. borderline tumors)

- History of another malignancy within the last 5 years, except for tumors with a
negligible risk for metastasis or death, such as adequately controlled basal-cell
carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
or breast

- Previous treatment with more than 2 chemotherapy regimens

- Any prior radiotherapy to the pelvis or abdomen

- Pre-existing peripheral neuropathy >/= CTC grade 2

- Inadequate organ function

- Uncontrolled hypertension or clinically significant cardiovascular disease

- Hepatitis B, hepatitis C or HIV infection

- Current chronic daily treatment with corticosteroids >/= 10 mg per day of
methylprednisolone or equivalent, excluding inhaled steroids History of receiving any
investigational treatment within 28 days prior to first study drug administration,
including prior enrollment into Part 1 of the study

- Concurrent participation in any clinical trial